<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">VALSARTAN</span><br/>(val-sar'tan)<br/><span class="topboxtradename">Diovan<br/></span><b>Classifications:</b> <span class="classification">cardiovascular agent</span>; <span class="classification">angiotensin ii-receptor (type at<sub>1</sub>) antagonist</span>; <span class="classification">antihypertensive</span><br/><b>Prototype: </b>Losartan<br/><b>Pregnancy Category: </b>C (first trimester); D (second and third trimesters)<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>40 mg, 80 mg, 160 mg capsules</p>
<h1><a name="action">Actions</a></h1>
<p>An angiotensin II receptor (type AT<sub>1</sub> antagonist; blocks the binding of angiotensin II to the AT<sub>1</sub> receptors found in many tissues (e.g., vascular smooth muscle, adrenal glands). Angiotensin II is a potent vasoconstrictor
         and primary vasoactive hormone of the reninangiotensinaldosterone system.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Blocks angiotensin II, which results in vasodilation and blocking of the aldosterone-secreting effects of angiotensin II,
         thus resulting in an antihypertensive effect.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Treatment of hypertension, heart failure.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to valsartan or losartan; pregnancy [(category C) first trimester, (category D) second and third trimesters],
         lactation; severe heart failure with compromised renal function.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Severe renal or hepatic impairment; congestive heart failure. Safety and efficacy in children 
      </p><h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Hypertension</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 80 mg q.d. (max: 320 mg q.d.)<br/><br/><span class="indicationtitle">Heart Failure</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> Start with 40 mg b.i.d. and titrate up to 160 mg b.i.d.<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give on an empty stomach.</li>
<li>Correct volume depletion prior to initiation of therapy to prevent hypotension.</li>
<li>Reduce dosage with severe hepatic or renal impairment.</li>
<li> 				Note: Daily dose may be titrated up to 320 mg. 			</li>
<li>Store at 15°30° C (59°86° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Arthralgia. <span class="typehead">CNS:</span> Headache, dizziness. <span class="typehead">GI:</span> Diarrhea, nausea. <span class="typehead">Respiratory:</span> Cough, sinusitis. <span class="typehead">Metabolic:</span> Hyperkalemia. 
      <h1><a name="interactions">Interactions</a></h1>No clinically significant interactions established. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Rapidly absorbed from GI tract, 25% bioavailability. <span class="typehead">Onset:</span> Blood pressure decreased in 2 wk. <span class="typehead">Peak:</span> Plasma levels, 24 h; blood pressure effect 4 wk. <span class="typehead">Distribution:</span> 99% protein bound. <span class="typehead">Metabolism:</span> Metabolized in the liver. <span class="typehead">Elimination:</span> Excreted primarily in feces. <span class="typehead">Half-Life:</span> 6 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor BP periodically; take trough readings, just prior to the next scheduled dose, when possible.</li>
<li>Lab tests: Monitor liver function tests, BUN and creatinine, serum potassium, and CBC with differential, periodically.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Inform physician immediately if you become pregnant.</li>
<li> 							Note: Maximum pressure lowering effect is usually evident between 2 and 4 wk after initiation of therapy. 						</li>
<li>Notify physician of episodes of dizziness, especially those that occur when making position changes.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>